Lymphoma

Latest News

After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL who were 65 or older or had comorbidities.
Zanubrutinib/Venetoclax Demonstrates Robust Efficacy in CLL/SLL

May 31st 2025

After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL who were 65 or older or had comorbidities.

Treatment with KITE-363 yields no dose-limiting toxicities in a first-in-human phase 1 study.
Novel CAR T-Cell Therapy Yields Responses in Relapsed/Refractory Lymphoma

May 31st 2025

China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL
China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL

May 22nd 2025

The FDA’s ODAC convened to discuss the potentially inconsistent treatment effects of glofitamab between regional subgroups in the phase 3 STARGLO trial.
FDA ODAC Votes 8-to-1 Against Applicability of Glofitamab DLBCL Data

May 20th 2025

Addressing Real-World Use of Liso-Cel vs Axi-Cel in DLBCL
Addressing Real-World Use of Liso-Cel vs Axi-Cel in DLBCL

May 17th 2025

More News